GC Green Cross Holdings Reports Q1 2026 Consolidated Net Loss of KRW 29.6B, Separate Net Profit of KRW 23.5B, Announces Medium-Term Dividend Policy

Consolidated revenue KRW 534.8B; subsidiary GC Pharma revenue KRW 435.5B (+13.5% YoY)
Consolidated operating profit KRW 3.1B, net loss KRW 29.6B (controlling interest loss KRW 17.3B)
Separate operating profit KRW 18.1B, net profit KRW 23.5B
Debt-to-equity ratio 139.5% (FY2025 end: 130.7%), net debt-to-equity ratio 81.0% (71.9%)
Medium-term shareholder return policy: target dividend payout of at least 50% of 3-year average separate net income
R&D expenditure ratio 9.5%, key pipelines (Hunterase ICV, ALYGLO, etc.) progressing